<DOC>
	<DOCNO>NCT00880100</DOCNO>
	<brief_summary>Multicenter , explorative , phase IIIb , open-label study ass efficacy safety Ultrase® MT12 , control steatorrhea clinical sign symptom malabsorption CF child pancreatic insufficiency ( PI ) . This study sponsor Aptalis Pharma ( formerly Axcan ) .</brief_summary>
	<brief_title>Use Ultrase® MT12 Young Cystic Fibrosis Children ( CF )</brief_title>
	<detailed_description>This multicenter , explorative , phase IIIb , open-label study patient CF PI . The study consist screen visit ( visit 1 ) , follow baseline phase 9 day ( plus 5-day window necessary ) regular pancreatic enzyme maintain 10 stool sample collect 5 day , baseline evaluation steatorrhea . Afterward , treatment phase 19 day ( plus 5-day window necessary ) Ultrase® MT12 follow ( usual pancreatic enzyme replace Ultrase® MT12 ) . Over last 5 day treatment phase , 10 additional stool sample collect , evaluation steatorrhea .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Male female patient age 2 6 year inclusively Patients current diagnosis CF base one typical clinical feature CF sibling CF positive newborn screen least either sweat chloride test great equal 60 millimoles/liter ( mmol/L ) quantitative pilocarpine iontophoresis two separate occasion two identifiable CFcausing mutation Patients presence PI demonstrate fecal elastase ( FE1 ) less 100 microgram/gram ( mcg/g ) stool ( perform ScheBo test ) require pancreatic enzyme supplementation Patients able eat highfat diet calculate value 2g 4g fat/kg body weight per day whole study current adequate nutritional status base body mass index ( BMI ) great equal fifth percentile Patients receive current treatment PI pancreatic enzymes The parent legal guardian sign informed consent form ( ICF ) mentally able understand comply study procedure Patients currently receive receive Ultrase® MT product ( MT12 , MT18 , MT20 ) PI last 30 day Patients known contraindication , sensitivity hypersensitivity Ultrase® porcine protein Patients presence medical condition know increase fecal fat loss could compromise study result study patient safety Patients current diagnosis history complete distal intestinal obstruction syndrome ( DIOS ) past 6 month 2 episode incomplete DIOS past year Patients use prohibited medication product study entry course study Patients chronic use narcotic Patients use bowel stimulant and/or laxative week Patients presence acute pancreatitis exacerbation chronic pancreatic disease Patients presence acute infection need treated oral intravenous ( IV ) broadspectrum antibiotic Patients history significant bowel resection ; small bowel resection meconium ileus birth appendectomy accept . Patients Presence dysmotility disorder Patients presence chronic severe abdominal pain Patients unable comply diet requirement Patients receive enteral tube feed overnight study entry need receive enteral tube feed overnight course study Patients history current diagnosis clinically significant portal hypertension Patients presence poorly control diabetes accord Investigator 's clinical judgment Patients condition prestudy laboratory abnormality history illness , opinion Investigator , might put patient risk , prevent patient completing study , otherwise affect outcome study Patient use investigational drug within 30 day prior date signature ICF</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Steatorrhea</keyword>
	<keyword>Malabsorption fat</keyword>
	<keyword>Pancreatic enzyme</keyword>
	<keyword>Abdominal pain</keyword>
	<keyword>Greasy stool</keyword>
</DOC>